Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 20/20 | 0.72 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.69 |
| ▸ | ABL1 | P00519 | 2/20 | 0.69 |
| ▸ | RET | P07949 | 2/20 | 0.69 |
| ▸ | ERBB4 | Q15303 | 2/20 | 0.69 |
| ▸ | CIT | O14578 | 1/20 | 0.68 |
| ▸ | GAK | O14976 | 1/20 | 0.68 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.68 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.68 |
| ▸ | STK10 | O94804 | 1/20 | 0.68 |
| ▸ | LCK | P06239 | 1/20 | 0.68 |
| ▸ | LYN | P07948 | 1/20 | 0.68 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.68 |
| ▸ | MET | P08581 | 1/20 | 0.68 |
| ▸ | HCK | P08631 | 1/20 | 0.68 |
| ▸ | SRC | P12931 | 1/20 | 0.68 |
| ▸ | PHKG2 | P15735 | 1/20 | 0.68 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.68 |
| ▸ | ERBB3 | P21860 | 1/20 | 0.68 |
| ▸ | AXL | P30530 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29043124 | 0.87 | EGFR (0.73) | EGFRERBB2ABL1RETERBB4 | |
| SCHEMBL4060171 | 0.87 | EGFR (0.75) | EGFRERBB2ABL1RETERBB4 | |
| SCHEMBL5425627 | 0.87 | EGFR (0.75) | EGFRERBB2ABL1RETERBB4 | |
| SCHEMBL15392264 | 0.86 | EGFR (0.58) | EGFRERBB2ERBB4 | |
| SCHEMBL28439806 | 0.85 | EGFR (0.80) | EGFRERBB2ABL1RETERBB4 | |
| SCHEMBL28439803 | 0.85 | EGFR (0.80) | EGFRERBB2ABL1RETERBB4 | |
| SCHEMBL2072074 | 0.85 | EGFR (0.75) | EGFRERBB2ABL1RETERBB4 | |
| SCHEMBL436188 | 0.85 | EGFR (0.75) | EGFRERBB2ABL1RETERBB4 | |
| SCHEMBL436189 | 0.85 | EGFR (0.75) | EGFRERBB2ABL1RETERBB4 | |
| SCHEMBL17498539 | 0.85 | EGFR (0.74) | EGFRERBB2ABL1RETERBB4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067593-B2 | Process for preparing aminocrotonylamino-substituted quinazoline derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-29 | — | — | US | disclosed |
| US-20110207929-A1 | Process for preparing aminocrotonylamino-substituted quinazoline derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-25 | — | — | US | disclosed |
| US-20110207932-A1 | Process for preparing aminocrotonylamino-substituted quinazoline derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-25 | — | — | US | disclosed |
| US-7960546-B2 | Process for preparing aminocrotonylamino-substituted quinazoline derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-14 | — | — | US | disclosed |
| US-20090306378-A1 | PROCESS FOR PREPARING AMINOCROTONYLAMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207932-A1 | Process for preparing aminocrotonylamino-substituted quinazoline derivatives | EGFR, CNKSR1, ERBB2 | EGFR 1/4885ERBB2 3/4885ABL1 11/4885 |
| US-20090306378-A1 | PROCESS FOR PREPARING AMINOCROTONYLAMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES | EGFR, CNKSR1, ERBB2 | EGFR 1/4885ERBB2 3/4885ABL1 11/4885 |
| US-20110207929-A1 | Process for preparing aminocrotonylamino-substituted quinazoline derivatives | EGFR, CNKSR1, ERBB2 | EGFR 1/4885ERBB2 3/4885ABL1 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.